CD357 (GITR) Antibody, anti-human, REAfinity™
Synonyms: TNFRSF18, AITR, GITR
RECOMBINANT EXTENDED VALIDATION
Bioz Star92/100 Bioz rating
2 Citations
Clone:
REA1007 | DT5D3
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD357 (GITR) Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
Biotin
PE
PE-Vio 615
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-116-961, 130-116-841
Description:
Human peripheral blood mononuclear cells (PBMCs) were stained with CD357 (GITR) antibodies or with the corresponding REA Control (S) antibodies (left images) as well as with CD4 antibodies and analyzed by flow cytometry using the MACSQuant® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application imageView details view details

Application imageView details view details
MICS (MACSima Imaging Cyclic Staining) applications
APC
PE
Fixation:
frozen – Acetone
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-116-961, 130-116-841
Testing grade:
Extended validation for CD357 (GITR) Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA1007
110416
high
108-17
high
AITR
high
DT5D3
high

Cells were incubated with an excess of purified unconjugated CD357 (GITR) (REA1007) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Knockout validation

To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.

WT
Extended-Validation detailed information image
KO
Extended-Validation detailed information image

Fluorescence microscopy image of CD357 (GITR) knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD357 (GITR)-PE (REA1007, red) and counterstained with DRAQ5 (blue) as DNA stain.

Extended-Validation detailed information image
Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD357 (GITR). Human peripheral blood mononuclear cells (PBMCs) stimulated with CD3/CD28 antibodies (T Cell TransAct™) for 3 days were stained with CD357 (GITR) antibodies and with a suitable counterstaining. As a control, CD357 (GITR) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD357 (GITR) shown as histograms

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD357 (GITR) (REA1007). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD357 (GITR) Antibody, anti-human, REAfinity™
Overview

Clone REA1007 recognizes the human CD357 antigen, also known as glucocorticoid-induced tumor necrosis factor receptor–related protein (GITR) or TNFRSF18, which is an inducible type I transmembrane protein and a member of the tumor necrosis factor receptor (TNFR) superfamily. CD357 is expressed at low levels on thymocyte subsets, resting T cells, B cells, and macrophages, and at high levels on CD4+CD25+ regulatory T cells (Tregs). Upon activation, expression on CD4+ and CD8+ T cells is upregulated. Triggering of GITR has been described to modulate Treg function and co-stimulate effector T cells. Stimulation of T cells through GITR can abrogate the inhibitory function of Tregs. It is hypothesized that GITR has a role in the maintenance of immunological self tolerance, and mouse models of autoimmune disease suggest that GITR activation may break self-tolerance and induce autoimmunity.

Additional information: Clone REA1007 displays negligible binding to Fc receptors.

Alternative names

TNFRSF18, AITR, GITR

Detailed product information

Technical specifications

Clone
REA1007
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD357 (GITR)
Molecular mass of antigen [kDa]
24
Distribution of antigen
B cells, macrophages, T cells, regulatory T cells, thymocytes
Entrez Gene ID
RRID
AB_2727716, AB_2727786, AB_2727788, AB_2727717, AB_2727789, AB_2727715, AB_2727787, AB_2727714

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD357 (GITR) Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support